{
    "2019-05-27": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Novartis Gets FDA Nod for Breast Cancer Drug & Gene Therapy",
                "features": {
                    "keywords": [
                        "Novartis",
                        "FDA",
                        "Breast Cancer",
                        "Gene Therapy"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "Incyte (INCY) Receives FDA Nod for Label Expansion of Jakafi",
                "features": {
                    "keywords": [
                        "Incyte",
                        "FDA",
                        "Label Expansion",
                        "Jakafi"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Novartis Gene Therapy Crosses The $2 Million Mark â€” Will Others Follow?",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Gene Therapy",
                        "$2 Million"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "Can Novartis Convince Insurers a $2.1 Million Gene Therapy Is a Great Deal?",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Insurers",
                        "$2.1 Million",
                        "Gene Therapy"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "insurance",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}